GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK reports that Japan's Ministry of Health, Labour and Welfare has accepted for review a new drug application for bepirovirsen as a treatment for adults with chronic hepatitis B. This is the first regulatory filing globally for the drug and follows positive phase III B-Well trial results showing statistically significant and clinically meaningful functional cure rates when added to standard therapy.
Bepirovirsen, an investigational antisense oligonucleotide, targets hepatitis B viral RNA to reduce viral replication and surface antigen levels, while stimulating the immune system. It has SENKU designation in Japan, which enables expedited review, and has also received Fast Track or similar designations in other major markets, but it is not yet approved anywhere.
GSK plc reports that on 25 February 2026 it repurchased 455,000 ordinary shares of 31¼ pence each through BNP Paribas at a volume-weighted average price of 2,209.58p, with prices ranging from 2,176.00p to 2,217.00p per share.
The shares will be held as treasury shares as part of its existing buyback programme started under a non-discretionary agreement on 17 February 2026, since when 3,161,000 shares have been bought. After this transaction, GSK holds 243,052,094 shares in treasury and has 4,073,100,332 shares in issue and voting rights, with treasury shares representing 5.97% of voting rights.
GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares through a company pension plan. The transaction involved the purchase of 11.163 ADS at a price of CAD 82.8205 per ADS on 2026-02-13 on the New York Stock Exchange.
GSK plc reported that non-executive director Dr Hal Barron acquired additional American Depositary Shares through his GSK 401(k) plan. The purchase resulted from the reinvestment of dividends, leading to the acquisition of 64 ADS at a price of $59.5200 per ADS.
The transaction took place on 2026-02-20 on the New York Stock Exchange (XNYS). This reflects automatic plan-based dividend reinvestment rather than an open‑market discretionary trade.
GSK plc has agreed to acquire Canada-based 35Pharma Inc., a private clinical-stage biopharma company, for $950 million in cash at closing. The deal adds HS235, a potential best-in-class activin signalling inhibitor for cardiopulmonary diseases, to GSK’s pipeline.
HS235 has completed phase I trials in healthy volunteers, with studies starting in pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction. GSK highlights HS235’s design to lower bleeding risk and its potential metabolic benefits, aiming to strengthen its Respiratory, Immunology and Inflammation portfolio in a pulmonary hypertension market forecast to reach $18 billion by 2032.
GSK plc reports that, acting through BNP Paribas, it repurchased 477,000 ordinary shares on 24 February 2026 as part of its existing share buyback programme. The shares were bought at prices between 2,175.00p and 2,217.00p per share, with a volume-weighted average price of 2,200.50p, and will be held as treasury shares.
Since 17 February 2026, GSK has repurchased a total of 2,706,000 ordinary shares. After this latest transaction, the company holds 242,597,094 ordinary shares in treasury and has 4,073,555,332 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights. GSK states that treasury shares now represent 5.96% of its voting rights.
GSK plc reported routine insider share transactions for two senior figures under its executive savings plans. Non-Executive Director Dr Hal Barron acquired 2,007.552 notional American Depositary Shares at $59.5200 per ADS on 20 February 2026 through automatic dividend reinvestment.
On the same date, James Ford, SVP and Group General Counsel, acquired 47.460 notional ADS, also at $59.5200 per ADS, via dividend reinvestment in his GSK Executive Supplemental Savings Plan account. Both transactions took place on the New York Stock Exchange.
GSK plc reports that, under its existing share buyback programme, it repurchased 462,000 ordinary shares of 31¼ pence each on 23 February 2026 through BNP Paribas. The lowest, highest and volume‑weighted average prices were 2,184.00p, 2,213.00p and 2,200.95p per share.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 2,229,000 ordinary shares. After these purchases, it holds 242,120,094 shares in treasury and has 4,074,032,332 ordinary shares in issue, which is also the total number of voting rights.
GSK states that, in line with DTR 5.5.1R, treasury shares now represent 5.94% of its voting rights. The filing also lists detailed trade-by-trade information across the London Stock Exchange and Cboe Europe venues, showing how the buyback was executed throughout the day.
GSK plc reports that, on 20 February 2026, it repurchased 467,000 ordinary shares of 31¼ pence each through BNP Paribas as part of its existing share buyback programme, at a volume-weighted average price of 2,223.53p, within a price range of 2,200.00p to 2,242.00p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 1,767,000 ordinary shares. Following this transaction, it holds 241,658,094 shares in treasury and has 4,074,494,332 ordinary shares in issue, which equals the total voting rights. Treasury shares represent 5.93% of voting rights.
GSK plc reported a share purchase by one of its board members. Independent Non-Executive Director Wendy Becker bought 3,334 ordinary shares of GSK at a price of £22.1926 per share. The transaction took place on 20 February 2026 on the London Stock Exchange.